← Leaderboards
Gal Bitan
University Of California Los Angeles
$9,187,343
Attributed
$9,187,343
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.8M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,187,343 · 7
By mechanism
RF1$4,639,564 · 2
R01$2,019,155 · 1
P01$1,280,471 · 1
R21$1,248,153 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Andre Elias Nel$21,296,649
- Ruben J. Boado$14,771,226
- David S Chia$9,399,833
- Otto O Yang$29,888,904
- Fernando Gomez-Pinilla$14,573,294
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposProteinsS DiseaseStructureFutureDesignModificationBaseToxic EffectBrainCharacteristicsAmyloid Beta-ProteinPreventTau ProteinsNeuronsLeadPublic HealthSideAffectIn VitroAmericanNeurofibrillary TanglesMolecularMouse Model
Grant awards (22)
A novel diagnostic assay for parkinsonian tauopathies$446,991
R21 · FY2025 · NS · contact PI
Biomarker discovery for parkinsonian diseases in extracellular vesicles from iPSC-derived neurons$180,717
RF1 · FY2024 · NS · contact PI
Biomarkers for parkinsonian disorders in CNS-originating extracellular vesicles$2,374,652
RF1 · FY2023 · NS · contact PI
Can diagnostic biomarkers for parkinsonian syndromes be measured in postmortem blood samples?$444,459
R21 · FY2023 · NS · contact PI
Investigation of the Effect of Structural Modifications of Tau on Assembly State and Seeding$137,112
RF1 · FY2021 · AG · contact PI
Misfolded protein clearance enhancers for Alzheimers therapy$315,700
R01 · FY2019 · AG · contact PI
Misfolded protein clearance enhancers for Alzheimers therapy$100,000
R01 · FY2019 · AG · contact PI
Misfolded protein clearance enhancers for Alzheimers therapy$383,766
R01 · FY2018 · AG · contact PI
Misfolded protein clearance enhancers for Alzheimers therapy$156,000
R01 · FY2018 · AG · contact PI
Investigation of the effect of structural modifications of tau on assembly state and seeding$1,947,083
RF1 · FY2017 · AG · contact PI
Misfolded protein clearance enhancers for Alzheimers therapy$315,700
R01 · FY2017 · AG · contact PI
Misfolded protein clearance enhancers for Alzheimers therapy$68,066
R01 · FY2017 · AG · contact PI
Misfolded protein clearance enhancers for Alzheimers therapy$315,700
R01 · FY2016 · AG · contact PI
Misfolded protein-clearance enhancers for Alzheimer's therapy$80,093
R01 · FY2016 · AG · contact PI
Misfolded protein clearance enhancers for Alzheimers therapy$284,130
R01 · FY2015 · AG · contact PI
DEVELOPMENT OF AMYLOID B-PROTEIN OLIGOMERIZATION INHIBITORS$268,261
P01 · FY2010 · AG · contact PI
DEVELOPMENT OF AMYLOID B-PROTEIN OLIGOMERIZATION INHIBITORS$262,390
P01 · FY2009 · AG · contact PI
DEVELOPMENT OF AMYLOID B-PROTEIN OLIGOMERIZATION INHIBITORS$253,784
P01 · FY2008 · AG · contact PI
Novel Specific Ligands for ABeta Oligomers$160,353
R21 · FY2008 · AG · contact PI
DEVELOPMENT OF AMYLOID B-PROTEIN OLIGOMERIZATION INHIBITORS$248,587
P01 · FY2007 · AG · contact PI
Novel Specific Ligands for ABeta Oligomers$196,350
R21 · FY2007 · AG · contact PI
DEVELOPMENT AMYLOID B-PROTEIN OLIGOMERIZATION INHIBITORS$247,449
P01 · FY2006 · AG · contact PI